Ascendis Pharma A (ASND) Amortizatization of Intangibles (2021 - 2025)
Ascendis Pharma A (ASND) posted Amortizatization of Intangibles of $150161.6 for Q4 2025, up 4.43% sequentially from $143793.8 in Q3 2025, and up 18.09% YoY from $127162.9 in Q4 2024.
Ascendis Pharma A (ASND) Amortizatization of Intangibles (2021 - 2025) Analysis & Trends
Ascendis Pharma A has reported Amortizatization of Intangibles for 5 years, with the latest figure at $150161.6 in Q4 2025.
- Quarterly Amortizatization of Intangibles rose 18.09% year-over-year to $150161.6 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $553832.8 (up 9.56% YoY) and the FY2025 annual result came in at $570381.3, up 14.3% from the prior year.
- Amortizatization of Intangibles advanced to $150161.6 in Q4 2025 per ASND's latest filing, from $143793.8 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $161391.0 in Q4 2023 and troughed at $111918.5 in Q3 2022.
- A 5-year average of $128817.0 and a median of $126729.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2023 and 2024: Amortizatization of Intangibles soared 42.51% in 2023, then dropped 21.21% in 2024.
- Over 5 years, Amortizatization of Intangibles stood at $128124.7 in 2021, then slipped by 11.61% to $113247.5 in 2022, then jumped by 42.51% to $161391.0 in 2023, then declined by 21.21% to $127162.9 in 2024, then increased by 18.09% to $150161.6 in 2025.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $150161.6, $143793.8, and $134703.2 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.33 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 678,000.00 |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 150,161.61 |
| Dec 31, 2025 | 150,161.61 |
| Sep 30, 2025 | 143,793.78 |
| Sep 30, 2025 | 143,793.78 |
| Jun 30, 2025 | 134,703.20 |
| Jun 30, 2025 | 134,703.20 |
| Mar 31, 2025 | 125,174.25 |
| Mar 31, 2025 | 125,174.25 |
| Dec 31, 2024 | 127,162.85 |
| Dec 31, 2024 | 127,162.85 |
| Sep 30, 2024 | 126,295.24 |
| Sep 30, 2024 | 126,295.24 |
| Jun 30, 2024 | 123,842.07 |
| Jun 30, 2024 | 123,842.07 |
| Mar 31, 2024 | 128,190.69 |
| Mar 31, 2024 | 128,190.69 |
| Dec 31, 2023 | 161,390.99 |
| Dec 31, 2023 | 161,390.99 |
| Sep 30, 2023 | 120,833.54 |
| Sep 30, 2023 | 120,833.54 |